IVBX.F Stock Overview
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Innovent Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.09 |
| 52 Week High | HK$6.40 |
| 52 Week Low | HK$3.83 |
| Beta | 0.25 |
| 11 Month Change | -13.81% |
| 3 Month Change | -5.83% |
| 1 Year Change | -7.55% |
| 33 Year Change | -46.98% |
| 5 Year Change | 41.25% |
| Change since IPO | 61.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVBX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.0% | -6.5% | -1.0% |
| 1Y | -7.5% | 14.6% | 30.3% |
Return vs Industry: IVBX.F underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: IVBX.F underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| IVBX.F volatility | |
|---|---|
| IVBX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IVBX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine IVBX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5,263 | Michael Yu | www.innoventbio.com |
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23.
Innovent Biologics, Inc. Fundamentals Summary
| IVBX.F fundamental statistics | |
|---|---|
| Market cap | US$8.16b |
| Earnings (TTM) | -US$176.84m |
| Revenue (TTM) | US$1.03b |
7.9x
P/S Ratio-46.2x
P/E RatioIs IVBX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVBX.F income statement (TTM) | |
|---|---|
| Revenue | CN¥7.46b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥5.34b |
| Other Expenses | CN¥6.62b |
| Earnings | -CN¥1.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 71.58% |
| Net Profit Margin | -17.18% |
| Debt/Equity Ratio | 25.8% |
How did IVBX.F perform over the long term?
See historical performance and comparison